A prospective observational study about fatigue in patients with unresectable pancreatic cancer who receive nab-paclitaxel plus gemcitabine therapy
Phase of Trial: Phase IV
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 04 Oct 2017 Status changed from active, no longer recruiting to completed.
- 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 13 May 2016 New trial record